SCHEDULE 13G/A 0001213900-21-051114 0001765710 XXXXXXXX LIVE 2 Voting Common Stock, par value $0.0001 09/30/2025 0001788028 Jasper Therapeutics, Inc. 471871202 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 Rule 13d-1(c) Qiming U.S. Healthcare Fund II, L.P. DE 0.00 928964.00 0.00 928964.00 928964.00 3.3 PN Qiming U.S. Healthcare GP II, LLC DE 0.00 928964.00 0.00 928964.00 928964.00 3.3 OO Mark McDade X1 0.00 928964.00 0.00 928964.00 928964.00 3.3 IN GARY E RIESCHEL X1 0.00 928964.00 0.00 928964.00 928964.00 3.3 IN Jasper Therapeutics, Inc. 2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA, 94065. The names of the persons filing this report (collectively, the "Reporting Persons") are: Qiming U.S. Healthcare Fund II, L.P. ("Qiming") Qiming U.S. Healthcare GP II, LLC ("Qiming GP") Mark McDade ("McDade") Gary Rieschel ("Reischel") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. Qiming U.S. 11100 NE 8th Street, Suite 200 Bellevue, WA 98004 Qiming Delaware Qiming GP Delaware McDade United States Rieschel United States Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. The Reporting Persons ownership of the Issuer's securities consists of 928,964 shares of voting common stock directly held by Qiming. Qiming GP is the general partner of Qiming. McDade and Rieschel are the managing partners of Qiming GP. Each of Qiming GP, McDade and Rieschel may be deemed to beneficially own the shares owned by Qiming. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 27,984,039 shares of voting common stock outstanding as of September 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 10, 2025. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on February 14, 2024). Qiming U.S. Healthcare Fund II, L.P. /s/ Mark McDade 11/14/2025 Qiming U.S. Healthcare GP II, LLC /s/ Mark McDade 11/14/2025 Mark McDade /s/ Mark McDade 11/14/2025 GARY E RIESCHEL /s/ Gary Rieschel 11/14/2025